Abstract:Abstract The 2017 Hormone Therapy Position Statement of The North American Menopause Society (NAMS) updates the 2012 Hormone Therapy Position Statement of The North American Menopause Society and identifies future research needs. An Advisory Panel of clinicians and researchers expert in the field of women's health and menopause was recruited by NAMS to review the 2012 Position Statement, evaluate new literature, assess the evidence, and reach consensus on recommendations, using the level of evidence to identify the strength of recommendations and the quality of the evidence. The Panel's recommendations were reviewed and approved by the NAMS Board of Trustees. Hormone therapy (HT) remains the most effective treatment for vasomotor symptoms (VMS) and the genitourinary syndrome of menopause (GSM) and has been shown to prevent bone loss and fracture. The risks of HT differ depending on type, dose, duration of use, route of administration, timing of initiation, and whether a progestogen is used. Treatment should be individualized to identify the most appropriate HT type, dose, formulation, route of administration, and duration of use, using the best available evidence to maximize benefits and minimize risks, with periodic reevaluation of the benefits and risks of continuing or discontinuing HT. For women aged younger than 60 years or who are within 10 years of menopause onset and have no contraindications, the benefit-risk ratio is most favorable for treatment of bothersome VMS and for those at elevated risk for bone loss or fracture. For women who initiate HT more than 10 or 20 years from menopause onset or are aged 60 years or older, the benefit-risk ratio appears less favorable because of the greater absolute risks of coronary heart disease, stroke, venous thromboembolism, and dementia. Longer durations of therapy should be for documented indications such as persistent VMS or bone loss, with shared decision making and periodic reevaluation. For bothersome GSM symptoms not relieved with over-the-counter therapies and without indications for use of systemic HT, low-dose vaginal estrogen therapy or other therapies are recommended. This NAMS position statement has been endorsed by Academy of Women's Health, American Association of Clinical Endocrinologists, American Association of Nurse Practitioners, American Medical Women's Association, American Society for Reproductive Medicine, Asociación Mexicana para el Estudio del Climaterio, Association of Reproductive Health Professionals, Australasian Menopause Society, Chinese Menopause Society, Colegio Mexicano de Especialistas en Ginecologia y Obstetricia, Czech Menopause and Andropause Society, Dominican Menopause Society, European Menopause and Andropause Society, German Menopause Society, Groupe d’études de la ménopause et du vieillissement Hormonal, HealthyWomen, Indian Menopause Society, International Menopause Society, International Osteoporosis Foundation, International Society for the Study of Women's Sexual Health, Israeli Menopause Society, Japan Society of Menopause and Women's Health, Korean Society of Menopause, Menopause Research Society of Singapore, National Association of Nurse Practitioners in Women's Health, SOBRAC and FEBRASGO, SIGMA Canadian Menopause Society, Società Italiana della Menopausa, Society of Obstetricians and Gynaecologists of Canada, South African Menopause Society, Taiwanese Menopause Society, and the Thai Menopause Society. The American College of Obstetricians and Gynecologists supports the value of this clinical document as an educational tool, June 2017. The British Menopause Society supports this Position Statement.

EMAS position statement: Thyroid disease and menopause

The essential menopause curriculum for healthcare professionals: A European Menopause and Andropause Society (EMAS) position statement

EMAS position statement: Testosterone replacement therapy in older men

EMAS position statement: Vitamin D and menopausal health

Sexual health and wellbeing and the menopause: An EMAS clinical guide

Thyroid Dysfunction in Periand Postmenopausal Women-Cumulative Risks

The 2017 hormone therapy position statement of The North American Menopause Society

EMAS position statement: Diet and health in midlife and beyond

Menopause and the workplace: consensus recommendations from The Menopause Society

Menopause and MHT in 2024: addressing the key controversies – an International Menopause Society White Paper

Maintaining the menopause momentum

Treating subclinical hypothyroidism in individuals with or without mental health problems -A Delphi based expert consensus study in two countries

Patients' persistent symptoms, clinician demographics and geo-economic factors are associated with choice of therapy for hypothyroidism by European thyroid specialists: The "THESIS"* collaboration (* T reatment of H ypothyroidism in Europe by S pecialists, an I nternational S urvey)

Estrogen deficiency in the menopause and the role of hormone therapy: integrating the findings of basic science research with clinical trials

2016 IMS Recommendations on women’s midlife health and menopause hormone therapy

Menopause: Questions and Answers for Improving Homeopathic Clinical Practice

Cultural issues in menopause: an exploratory qualitative study of Macedonian women in Australia

Effectiveness and safety of menopause treatments: pitfalls of available evidence and future research need

The role of androgens in the treatment of genitourinary syndrome of menopause (GSM): International Society for the Study of Women's Sexual Health (ISSWSH) expert consensus panel review

Androgen deficiency in hypopituitary women: its consequences and management

Thyroid Dysfunction and its Correlation with Section Metabolic Syndrome among Perimenopausal and Postmenopausal Women Attending a Tertiary Care Hospital in Karnataka: A Cross-sectional Study